Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingBCBS Massachusetts Molecular Testing Update | Open…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - MassachusettsPolicy 029

    Molecular Testing in the Management of Pulmonary Nodules

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 029 alerts

    Get alerted when Policy 029 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for plasma-based proteomic screening and related molecular testing used to risk-stratify undiagnosed pulmonary nodules detected by computed tomography for applicable commercial and Medicare Advantage members.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyMolecular Testing in the Management of Pulmonary Nodules
    Policy CodePolicy 029
    Change TypeModified
    Effective DateOctober 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification or preauthorization for all products when a service described in this policy is performed inpatient.
    SourceLink
    POLICY UPDATE CHANGES

    The policy statement and evidence review for the Percepta Genomic Sequencing Classifier were removed because the product is no longer marketed.

    The REVEAL Lung Nodule Characterization test by MagArray was removed from the policy statements because the company is no longer in business.

    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Investigational CPT codes
    97%Nodify XL2 specificity
    65%REVEAL identification rate
    ≤50%Nodify XL2 validation threshold
    InsufficientEvidence determination

    Coverage Criteria

    Plasma-based proteomic screening

    The service is considered investigational rather than covered.

    Investigational plasma-based proteomic screening: Plasma-based proteomic screening, including but not limited to Nodify XL2 (BDX-XL2) and Nodify CDT, in individuals with undiagnosed pulmonary nodules detected by computed tomography is considered investigational.

    Applies to Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity.

    Code-specific investigational designations

    The following molecular testing codes are considered investigational for the listed products.

    Investigational CPT codes: CPT code 0092U is considered investigational for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue, and Medicare PPO Blue. CPT code 0080U is considered investigational for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity.

    See the coding section for exact code descriptions.

    Plasma-based proteomic screening, including but not limited to Nodify XL2 (BDX-XL2) and Nodify CDT, is considered investigational for individuals with undiagnosed pulmonary nodules detected by computed tomography. This applies to Commercial Members enrolled in Managed Care (HMO and POS), PPO, and Indemnity products.

    For services described in this policy, plasma-based proteomic screening is not covered when performed on an outpatient basis for members enrolled in Commercial PPO and Indemnity products.

    Coding Information

    Investigational CPT Code — Commercial Managed Care, PPO, Indemnity, Medicare HMO Blue, and Medicare PPO BlueCPTExperimental
    0092UOncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy
    Investigational CPT Code — Commercial Managed Care, PPO, and IndemnityCPTExperimental
    0080UOncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy
    Nodify XL2 validation population
    PopulationPatients with a low-to-moderate pretest probability of a malignant pulmonary nodule
    Pretest probability≤50%
    Test evaluatedNodify XL2 version 2 (formerly Xpresys Lung version 2)
    Nodify XL2 version 2 specificity
    Specificity97%
    ClassifierNodify XL2 version 2
    Evaluated population

    Provider Actions and Authorization

    Prior Authorization

    Inpatient Authorization Required

    Precertification/preauthorization is required for all products when a service described in this policy is performed inpatient.

    Denial Risk

    Outpatient Commercial PPO and Indemnity Noncoverage

    For services described in this policy performed outpatient, the service is not covered for Commercial PPO and Indemnity products.

    • Outpatient: Commercial PPO and Indemnity — not a covered service.
    Documentation Required

    Clinical Background

    Pulmonary nodules may be detected incidentally on chest imaging or during lung cancer screening. Management depends on radiographic characteristics and patient-specific factors. Molecular tests, including plasma-based proteomic screening and gene expression profiling of bronchial brushing, have been proposed to help risk-stratify nodules and determine whether invasive diagnostic procedures may be needed. Nodify XL2 and Nodify CDT are intended to help rule out or rule in invasive diagnostic procedures; they do not diagnose lung cancer.

    Definitions and Test Descriptions

    Proteomics
    DefinitionThe study of the structure and function of proteins
    Characteristics examinedProtein concentration, structure, and other characteristics
    Materials studiedVarious bodily tissues, fluids, and other materials
    Mass spectrometry
    TechniqueAn analytic technique that ionizes proteins into smaller fragments
    MeasurementsDetermines mass and composition
    ApplicationIdentifies and characterizes proteins

    Not Covered Services

    The following services are considered not covered because they are investigational: plasma-based proteomic screening for undiagnosed computed tomography-detected pulmonary nodules, including Nodify XL2 and Nodify CDT, and CPT codes 0092U and 0080U for the applicable member products.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyMolecular Testing in the Management of Pulmonary Nodules
    Policy CodePolicy 029
    Change TypeModified
    Effective DateOctober 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification or preauthorization for all products when a service described in this policy is performed inpatient.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider Actions and AuthorizationClinical BackgroundDefinitions and Test DescriptionsNot Covered Services
    Patients with a low-to-moderate pretest probability (≤50%) of a malignant pulmonary nodule
    REVEAL model identification rate
    Identification rate65% of intermediate-risk samples
    ClassificationsIdentified as either low risk or high risk
    ModelREVEAL model
    REVEAL model negative predictive value
    Negative predictive value94%
    ModelREVEAL model
    Study contextValidation of molecular testing for undiagnosed pulmonary nodules detected by computed tomography
    REVEAL model sensitivity
    Sensitivity94%
    ModelREVEAL model
    Reported withNegative predictive value of 94%

    Current Coding and Benefit Verification

    Report all services using the most up-to-date industry-standard codes and verify member benefits and reimbursement before service. Code inclusion or exclusion does not determine individual member coverage.

    • Use current procedure, revenue, and diagnosis codes, including modifiers where applicable.
    • Refer to the member’s contract benefits in effect at the time of service to determine coverage or noncoverage.
    Denial Risk

    Investigational Pulmonary Nodule Molecular Testing

    Plasma-based proteomic screening for individuals with undiagnosed pulmonary nodules detected by computed tomography is considered investigational, including but not limited to Nodify XL2 (BDX-XL2) and Nodify CDT.

    • CPT 0092U: Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as a risk score for likelihood of malignancy.
    • CPT 0080U: Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors, utilizing plasma, algorithm reported as a categorical probability of malignancy.
    • Investigational designation applies to the applicable Commercial Members products identified in the policy.
    Gene expression profiling
    DefinitionMeasurement of the activity of genes within cells
    Clinical purposeDetects cancer-associated gene expression in clinical samples
    Risk assessmentAssesses the risk for malignancy
    Nodify XL2
    Test typePlasma-based proteomic screening test
    MeasurementMeasures the relative abundance of proteins from multiple disease pathways associated with lung cancer
    Analytic methodMultiple reaction monitoring mass spectrometry
    Nodify CDT
    Test typeProteomic test
    TechnologyMulti-analyte immunoassay technology
    Analytes measuredAutoantibodies associated with tumor antigens